Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 98

1.

Effect of Statin on Cancer Incidence: An Umbrella Systematic Review and Meta-Analysis.

Jeong GH, Lee KH, Kim JY, Eisenhut M, Kronbichler A, van der Vliet HJ, Hong SH, Shin JI, Gamerith G.

J Clin Med. 2019 Jun 8;8(6). pii: E819. doi: 10.3390/jcm8060819.

2.

Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parallel-group, phase II-III, randomised, superiority study (CAIRO6)

Rovers KP, Bakkers C, Simkens GAAM, Burger JWA, Nienhuijs SW, Creemers GM, Thijs AMJ, Brandt-Kerkhof ARM, Madsen EVE, Ayez N, de Boer NL, van Meerten E, Tuynman JB, Kusters M, Sluiter NR, Verheul HMW, van der Vliet HJ, Wiezer MJ, Boerma D, Wassenaar ECE, Los M, Hunting CB, Aalbers AGJ, Kok NFM, Kuhlmann KFD, Boot H, Chalabi M, Kruijff S, Been LB, van Ginkel RJ, de Groot DJA, Fehrmann RSN, de Wilt JHW, Bremers AJA, de Reuver PR, Radema SA, Herbschleb KH, van Grevenstein WMU, Witkamp AJ, Koopman M, Haj Mohammad N, van Duyn EB, Mastboom WJB, Mekenkamp LJM, Nederend J, Lahaye MJ, Snaebjornsson P, Verhoef C, van Laarhoven HWM, Zwinderman AH, Bouma JM, Kranenburg O, van 't Erve I, Fijneman RJA, Dijkgraaf MGW, Hemmer PHJ, Punt CJA, Tanis PJ, de Hingh IHJT; Dutch Peritoneal Oncology Group (DPOG); Dutch Colorectal Cancer Group (DCCG).

BMC Cancer. 2019 Apr 25;19(1):390. doi: 10.1186/s12885-019-5545-0.

3.

Optimal treatment of opioid induced constipation in daily clinical practice - an observational study.

Neefjes ECW, van der Wijngaart H, van der Vorst MJDL, Ten Oever D, van der Vliet HJ, Beeker A, Rhodius CA, van den Berg HP, Berkhof J, Verheul HMW.

BMC Palliat Care. 2019 Mar 29;18(1):31. doi: 10.1186/s12904-019-0416-7.

4.

Metronomic cyclophosphamide attenuates mTOR-mediated expansion of regulatory T cells, but does not impact clinical outcome in patients with metastatic renal cell cancer treated with everolimus.

Werter IM, Huijts CM, Lougheed SM, Hamberg P, Polee MB, Tascilar M, Los M, Haanen JBAG, Helgason HH, Verheul HM, de Gruijl TD, van der Vliet HJ; Dutch WIN-O Consortium.

Cancer Immunol Immunother. 2019 May;68(5):787-798. doi: 10.1007/s00262-019-02313-z. Epub 2019 Feb 11.

PMID:
30756132
5.

Incidence of Capillary Leak Syndrome as an Adverse Effect of Drugs in Cancer Patients: A Systematic Review and Meta-Analysis.

Jeong GH, Lee KH, Lee IR, Oh JH, Kim DW, Shin JW, Kronbichler A, Eisenhut M, van der Vliet HJ, Abdel-Rahman O, Stubbs B, Solmi M, Veronese N, Dragioti E, Koyanagi A, Radua J, Shin JI.

J Clin Med. 2019 Jan 26;8(2). pii: E143. doi: 10.3390/jcm8020143.

6.

The effect of everolimus and low-dose cyclophosphamide on immune cell subsets in patients with metastatic renal cell carcinoma: results from a phase I clinical trial.

Huijts CM, Lougheed SM, Bodalal Z, van Herpen CM, Hamberg P, Tascilar M, Haanen JB, Verheul HM, de Gruijl TD, van der Vliet HJ; Dutch WIN-O Consortium.

Cancer Immunol Immunother. 2019 Mar;68(3):503-515. doi: 10.1007/s00262-018-2288-8. Epub 2019 Jan 17.

7.

Corrigendum: CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: α-Galactosylceramide and Beyond.

King LA, Lameris R, de Gruijl TD, van der Vliet HJ.

Front Immunol. 2018 Nov 20;9:2606. doi: 10.3389/fimmu.2018.02606. eCollection 2018.

8.

Bayesian statistical methods in genetic association studies: Empirical examination of statistically non-significant Genome Wide Association Study (GWAS) meta-analyses in cancers: A systematic review.

Park JH, Geum DI, Eisenhut M, van der Vliet HJ, Shin JI.

Gene. 2019 Feb 15;685:170-178. doi: 10.1016/j.gene.2018.10.057. Epub 2018 Oct 26.

PMID:
30416053
9.

Phase 1 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell carcinoma.

Huijts CM, Werter IM, Lougheed SM, Goedegebuure RS, van Herpen CM, Hamberg P, Tascilar M, Haanen JB, Verheul HM, de Gruijl TD, van der Vliet HJ; Dutch WIN-O Consortium.

Cancer Immunol Immunother. 2019 Feb;68(2):319-329. doi: 10.1007/s00262-018-2248-3. Epub 2018 Nov 9.

10.

Systemic Capillary Leak Syndrome (Clarkson Syndrome) in Cancer Patients: A Systematic Review.

Shin JI, Lee KH, Lee IR, Oh JH, Kim DW, Shin JW, Eo TS, Kronbichler A, Eisenhut M, van der Vliet HJ.

J Clin Med. 2018 Nov 6;7(11). pii: E418. doi: 10.3390/jcm7110418.

11.

Nanobody-Fc constructs targeting chemokine receptor CXCR4 potently inhibit signaling and CXCR4-mediated HIV-entry and induce antibody effector functions.

Bobkov V, Zarca AM, Van Hout A, Arimont M, Doijen J, Bialkowska M, Toffoli E, Klarenbeek A, van der Woning B, van der Vliet HJ, Van Loy T, de Haard H, Schols D, Heukers R, Smit MJ.

Biochem Pharmacol. 2018 Dec;158:413-424. doi: 10.1016/j.bcp.2018.10.014. Epub 2018 Oct 17.

12.

Positive & Negative Roles of Innate Effector Cells in Controlling Cancer Progression.

Stolk D, van der Vliet HJ, de Gruijl TD, van Kooyk Y, Exley MA.

Front Immunol. 2018 Sep 21;9:1990. doi: 10.3389/fimmu.2018.01990. eCollection 2018. Review.

13.

Reply to the letter to the editor 'Body mass index and 20-specific cancers-re-analyses of dose-response meta-analyses of observational studies' by Markozannes et al.

Choi EK, Eisenhut M, van der Vliet HJ, Lee KH, Shin JI.

Ann Oncol. 2018 Nov 1;29(11):2265-2266. doi: 10.1093/annonc/mdy400. No abstract available.

PMID:
30215684
14.

Improving CLL Vγ9Vδ2-T-cell fitness for cellular therapy by ex vivo activation and ibrutinib.

de Weerdt I, Hofland T, Lameris R, Endstra S, Jongejan A, Moerland PD, de Bruin RCG, Remmerswaal EBM, Ten Berge IJM, Liu N, van der Stelt M, Faber LM, Levin MD, Eldering E, Tonino SH, de Gruijl TD, van der Vliet HJ, Kater AP.

Blood. 2018 Nov 22;132(21):2260-2272. doi: 10.1182/blood-2017-12-822569. Epub 2018 Sep 13.

PMID:
30213872
15.

Selection of Protein Kinase Inhibitors Based on Tumor Tissue Kinase Activity Profiles in Patients with Refractory Solid Malignancies: An Interventional Molecular Profiling Study.

Labots M, Van der Mijn JC, Dekker H, Ruijter R, Pham TV, Van der Vliet HJ, Van der Hoeven JJM, Meijer GA, Verheul HMW.

Oncologist. 2018 Oct;23(10):1135-e118. doi: 10.1634/theoncologist.2018-0263. Epub 2018 Jul 17.

16.

CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: α-Galactosylceramide and Beyond.

King LA, Lameris R, de Gruijl TD, van der Vliet HJ.

Front Immunol. 2018 Jul 2;9:1519. doi: 10.3389/fimmu.2018.01519. eCollection 2018. Review. Erratum in: Front Immunol. 2018 Nov 20;9:2606.

17.

Outcomes and Treatment Options for Duodenal Adenocarcinoma: A Systematic Review and Meta-Analysis.

Meijer LL, Alberga AJ, de Bakker JK, van der Vliet HJ, Le Large TYS, van Grieken NCT, de Vries R, Daams F, Zonderhuis BM, Kazemier G.

Ann Surg Oncol. 2018 Sep;25(9):2681-2692. doi: 10.1245/s10434-018-6567-6. Epub 2018 Jun 26.

18.

Randomized phase 2 study of gemcitabine and cisplatin with or without vitamin supplementation in patients with advanced esophagogastric cancer.

van Zweeden AA, van Groeningen CJ, Honeywell RJ, Giovannetti E, Ruijter R, Smorenburg CH, Giaccone G, Verheul HMW, Peters GJ, van der Vliet HJ.

Cancer Chemother Pharmacol. 2018 Jul;82(1):39-48. doi: 10.1007/s00280-018-3588-6. Epub 2018 Apr 25.

19.

A safety and immunogenicity study of immunization with hVEGF26-104/RFASE in cynomolgus monkeys.

Wentink MQ, Verheul HMW, Griffioen AW, Schafer KA, McPherson S, Early RJ, van der Vliet HJ, de Gruijl TD.

Vaccine. 2018 Apr 5;36(15):2025-2032. doi: 10.1016/j.vaccine.2018.02.066. Epub 2018 Mar 5.

20.

Body mass index and 20 specific cancers: re-analyses of dose-response meta-analyses of observational studies.

Choi EK, Park HB, Lee KH, Park JH, Eisenhut M, van der Vliet HJ, Kim G, Shin JI.

Ann Oncol. 2018 Mar 1;29(3):749-757. doi: 10.1093/annonc/mdx819.

PMID:
29300814
21.

A bispecific nanobody approach to leverage the potent and widely applicable tumor cytolytic capacity of Vγ9Vδ2-T cells.

de Bruin RCG, Veluchamy JP, Lougheed SM, Schneiders FL, Lopez-Lastra S, Lameris R, Stam AG, Sebestyen Z, Kuball J, Molthoff CFM, Hooijberg E, Roovers RC, Santo JPD, van Bergen En Henegouwen PMP, Verheul HMW, de Gruijl TD, van der Vliet HJ.

Oncoimmunology. 2017 Oct 20;7(1):e1375641. doi: 10.1080/2162402X.2017.1375641. eCollection 2017.

22.

The effects of systemic treatment with aminobisphosphonates and statins on circulating Vγ9Vδ2-T cells in patients with advanced cancer.

Schneiders FL, Huijts CM, Reijm M, Bontkes HJ, Verheul HMW, de Gruijl TD, van der Vliet HJ.

Immunobiology. 2018 Feb;223(2):171-177. doi: 10.1016/j.imbio.2017.10.029. Epub 2017 Oct 16.

PMID:
29055564
23.

Immunological effects of everolimus in patients with metastatic renal cell cancer.

Huijts CM, Santegoets SJ, de Jong TD, Verheul HM, de Gruijl TD, van der Vliet HJ.

Int J Immunopathol Pharmacol. 2017 Dec;30(4):341-352. doi: 10.1177/0394632017734459. Epub 2017 Oct 9.

24.

The Rise of Allogeneic Natural Killer Cells As a Platform for Cancer Immunotherapy: Recent Innovations and Future Developments.

Veluchamy JP, Kok N, van der Vliet HJ, Verheul HMW, de Gruijl TD, Spanholtz J.

Front Immunol. 2017 May 31;8:631. doi: 10.3389/fimmu.2017.00631. eCollection 2017. Review.

25.

Correction: Prevention of Vγ9Vδ2 T Cell Activation by a Vγ9Vδ2 TCR Nanobody.

de Bruin RCG, Stam AGM, Vangone A, van Bergen En Henegouwen PMP, Verheul HMW, Sebestyén Z, Kuball J, Bonvin AMJJ, de Gruijl TD, van der Vliet HJ.

J Immunol. 2017 May 1;198(9):3759. doi: 10.4049/jimmunol.1700317. No abstract available.

26.

Statistical controversies in clinical research: overlap and errors in the meta-analyses of microRNA genetic association studies in cancers.

Park JH, Eisenhut M, van der Vliet HJ, Shin JI.

Ann Oncol. 2017 Jun 1;28(6):1169-1182. doi: 10.1093/annonc/mdx024.

PMID:
28327894
27.

Standardized and flexible eight colour flow cytometry panels harmonized between different laboratories to study human NK cell phenotype and function.

Veluchamy JP, Delso-Vallejo M, Kok N, Bohme F, Seggewiss-Bernhardt R, van der Vliet HJ, de Gruijl TD, Huppert V, Spanholtz J.

Sci Rep. 2017 Mar 10;7:43873. doi: 10.1038/srep43873.

28.

In Vivo Efficacy of Umbilical Cord Blood Stem Cell-Derived NK Cells in the Treatment of Metastatic Colorectal Cancer.

Veluchamy JP, Lopez-Lastra S, Spanholtz J, Bohme F, Kok N, Heideman DA, Verheul HM, Di Santo JP, de Gruijl TD, van der Vliet HJ.

Front Immunol. 2017 Feb 6;8:87. doi: 10.3389/fimmu.2017.00087. eCollection 2017.

29.

Prevention of Vγ9Vδ2 T Cell Activation by a Vγ9Vδ2 TCR Nanobody.

de Bruin RC, Stam AG, Vangone A, van Bergen En Henegouwen PM, Verheul HM, Sebestyén Z, Kuball J, Bonvin AM, de Gruijl TD, van der Vliet HJ.

J Immunol. 2017 Jan 1;198(1):308-317. Epub 2016 Nov 28. Erratum in: J Immunol. 2017 May 1;198(9):3759.

30.

High-efficiency lysis of cervical cancer by allogeneic NK cells derived from umbilical cord progenitors is independent of HLA status.

Veluchamy JP, Heeren AM, Spanholtz J, van Eendenburg JD, Heideman DA, Kenter GG, Verheul HM, van der Vliet HJ, Jordanova ES, de Gruijl TD.

Cancer Immunol Immunother. 2017 Jan;66(1):51-61. doi: 10.1007/s00262-016-1919-1. Epub 2016 Oct 25.

31.

A functional bioassay to determine the activity of anti-VEGF antibody therapy in blood of patients with cancer.

Wentink MQ, Broxterman HJ, Lam SW, Boven E, Walraven M, Griffioen AW, Pili R, van der Vliet HJ, de Gruijl TD, Verheul HM.

Br J Cancer. 2016 Oct 11;115(8):940-948. doi: 10.1038/bjc.2016.275. Epub 2016 Aug 30.

32.

Highly specific and potently activating Vγ9Vδ2-T cell specific nanobodies for diagnostic and therapeutic applications.

de Bruin RCG, Lougheed SM, van der Kruk L, Stam AG, Hooijberg E, Roovers RC, van Bergen En Henegouwen PMP, Verheul HMW, de Gruijl TD, van der Vliet HJ.

Clin Immunol. 2016 Aug;169:128-138. doi: 10.1016/j.clim.2016.06.012. Epub 2016 Jun 30.

33.

Combination of NK Cells and Cetuximab to Enhance Anti-Tumor Responses in RAS Mutant Metastatic Colorectal Cancer.

Veluchamy JP, Spanholtz J, Tordoir M, Thijssen VL, Heideman DA, Verheul HM, de Gruijl TD, van der Vliet HJ.

PLoS One. 2016 Jun 17;11(6):e0157830. doi: 10.1371/journal.pone.0157830. eCollection 2016.

34.

Generation and characterization of CD1d-specific single-domain antibodies with distinct functional features.

Lameris R, de Bruin RC, van Bergen En Henegouwen PM, Verheul HM, Zweegman S, de Gruijl TD, van der Vliet HJ.

Immunology. 2016 Sep;149(1):111-21. doi: 10.1111/imm.12635.

35.

Differential effects of inhibitors of the PI3K/mTOR pathway on the expansion and functionality of regulatory T cells.

Huijts CM, Santegoets SJ, Quiles Del Rey M, de Haas RR, Verheul HM, de Gruijl TD, van der Vliet HJ.

Clin Immunol. 2016 Jul;168:47-54. doi: 10.1016/j.clim.2016.05.005. Epub 2016 May 14.

36.

Response to Comment on "mTOR Inhibition Per Se Induces Nuclear Localization of FOXP3 and Conversion of Invariant NKT (iNKT) Cells into Immunosuppressive Regulatory iNKT Cells".

Huijts CM, de Gruijl TD, van der Vliet HJ.

J Immunol. 2015 Dec 1;195(11):5101-2. doi: 10.4049/jimmunol.1502170. No abstract available.

37.

mTOR Inhibition Per Se Induces Nuclear Localization of FOXP3 and Conversion of Invariant NKT (iNKT) Cells into Immunosuppressive Regulatory iNKT Cells.

Huijts CM, Schneiders FL, Garcia-Vallejo JJ, Verheul HM, de Gruijl TD, van der Vliet HJ.

J Immunol. 2015 Sep 1;195(5):2038-45. doi: 10.4049/jimmunol.1402710. Epub 2015 Aug 3.

38.

Phase I Clinical Trial to Determine the Feasibility and Maximum Tolerated Dose of Panitumumab to Standard Gemcitabine-Based Chemoradiation in Locally Advanced Pancreatic Cancer.

van Zweeden AA, van der Vliet HJ, Wilmink JW, Meijerink MR, Meijer OW, Bruynzeel AM, van Tienhoven G, Giovannetti E, Kazemier G, Jacobs MA, Verheul HM.

Clin Cancer Res. 2015 Oct 15;21(20):4569-75. doi: 10.1158/1078-0432.CCR-14-3364. Epub 2015 Jun 8.

39.

Vγ9Vδ2-T cells as antigen presenting cells for iNKT cell based cancer immunotherapy.

Werter IM, Schneiders FL, Scotet E, Verheul HM, de Gruijl TD, van der Vliet HJ.

Oncoimmunology. 2014 Dec 8;3(9):e955343. eCollection 2014 Oct.

40.

Aminobisphosphonates inhibit dendritic cell-mediated antigen-specific activation of CD1d-restricted iNKT cells.

Schneiders FL, Huijts CM, Mantici A, Menks MA, Scotet E, Veerhuis R, Verheul HM, de Gruijl TD, van der Vliet HJ.

Clin Immunol. 2015 May;158(1):92-9. doi: 10.1016/j.clim.2015.03.007. Epub 2015 Mar 18.

PMID:
25796193
41.

Mechanisms of intimate and long-distance cross-talk between glioma and myeloid cells: how to break a vicious cycle.

Wurdinger T, Deumelandt K, van der Vliet HJ, Wesseling P, de Gruijl TD.

Biochim Biophys Acta. 2014 Dec;1846(2):560-75. doi: 10.1016/j.bbcan.2014.10.003. Epub 2014 Oct 20. Review.

PMID:
25453365
42.

Preoperative chemoradiation therapy in combination with panitumumab for patients with resectable esophageal cancer: the PACT study.

Kordes S, van Berge Henegouwen MI, Hulshof MC, Bergman JJ, van der Vliet HJ, Kapiteijn E, van Laarhoven HW, Richel DJ, Klinkenbijl JH, Meijer SL, Wilmink JW.

Int J Radiat Oncol Biol Phys. 2014 Sep 1;90(1):190-6. doi: 10.1016/j.ijrobp.2014.05.022.

PMID:
25195993
43.

Bispecific antibody platforms for cancer immunotherapy.

Lameris R, de Bruin RC, Schneiders FL, van Bergen en Henegouwen PM, Verheul HM, de Gruijl TD, van der Vliet HJ.

Crit Rev Oncol Hematol. 2014 Dec;92(3):153-65. doi: 10.1016/j.critrevonc.2014.08.003. Epub 2014 Aug 20. Review.

PMID:
25195094
44.

Clinical evaluation of the efficacy of methylnaltrexone in resolving constipation induced by different opioid subtypes combined with laboratory analysis of immunomodulatory and antiangiogenic effects of methylnaltrexone.

Neefjes EC, van der Vorst MJ, Boddaert MS, Zuurmond WW, van der Vliet HJ, Beeker A, van den Berg HP, van Groeningen CJ, Vrijaldenhoven S, Verheul HM.

BMC Palliat Care. 2014 Aug 20;13:42. doi: 10.1186/1472-684X-13-42. eCollection 2014.

45.

CD1d-restricted antigen presentation by Vγ9Vδ2-T cells requires trogocytosis.

Schneiders FL, Prodöhl J, Ruben JM, O'Toole T, Scheper RJ, Bonneville M, Scotet E, Verheul HM, de Gruijl TD, van der Vliet HJ.

Cancer Immunol Res. 2014 Aug;2(8):732-40. doi: 10.1158/2326-6066.CIR-13-0167. Epub 2014 Apr 21.

46.

Exploiting the CD1d-iNKT cell axis for potentiation of DC-based cancer vaccines.

Lameris R, Schneiders FL, de Gruijl TD, van der Vliet HJ.

Methods Mol Biol. 2014;1139:155-65. doi: 10.1007/978-1-4939-0345-0_14.

PMID:
24619678
47.

Ex vivo analysis of resident hepatic pro-inflammatory CD1d-reactive T cells and hepatocyte surface CD1d expression in hepatitis C.

Yanagisawa K, Yue S, van der Vliet HJ, Wang R, Alatrakchi N, Golden-Mason L, Schuppan D, Koziel MJ, Rosen HR, Exley MA.

J Viral Hepat. 2013 Aug;20(8):556-65. doi: 10.1111/jvh.12081. Epub 2013 Mar 11.

48.

Reversible posterior leukoencephalopathy syndrome during sunitinib therapy for metastatic renal cell carcinoma.

Hadj JO, Braven RD, Tillier C, Schrijver HM, Verheul HM, VAN DER Vliet HJ.

Oncol Lett. 2012 Jun;3(6):1293-1296. Epub 2012 Mar 16.

49.

Irinotecan-induced dysarthria.

Dressel AJ, van der Mijn JC, Aalders IJ, Rinkel RN, van der Vliet HJ.

Case Rep Oncol. 2012 Jan;5(1):47-51. doi: 10.1159/000336156. Epub 2012 Jan 18.

50.

An α-galactosylceramide nose job shapes up iNKT cells.

de Bruin RC, Schneiders FL, Santegoets SJ, Verheul HM, de Gruijl TD, van der Vliet HJ.

Immunotherapy. 2012 Jan;4(1):20-1. No abstract available.

PMID:
22263254

Supplemental Content

Loading ...
Support Center